- Home
- GNE vs VCRE Comparison
GNE vs VCRE Comparison
Compare GNE & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GNE | VCRE |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Sweden |
| Employees | N/A | 40 |
| Industry | Power Generation | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 316.4M |
| IPO Year | 2011 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GNE | VCRE |
|---|---|---|
| Price | $15.52 | $11.50 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 62.8K | 8.3K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.65 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $425,202,000.00 | N/A |
| Revenue This Year | $17.49 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $28.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.69 | $10.47 |
| 52 Week High | $16.28 | $13.15 |
Technical Indicators
Market Signals| Indicator | GNE | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 46.13 |
| Support Level | $13.45 | $10.83 |
| Resistance Level | $15.50 | $13.00 |
| Average True Range (ATR) | 0.47 | 0.75 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 78.71 | 40.30 |
Price Performance
Historical ComparisonAbout GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.